Last edition
News about "commercialisation rights "
Samsung Bioepis Relaunches Byooviz in US Through Commercial Partnership with Harrow
Samsung Bioepis has relaunched its ophthalmology biosimilar Byooviz in the US through its partnership with Harrow, expanding access to a lower-cost treatment option for patients with retinal diseases, including wet age-related macular degeneration.
Commercialisation Rights | 03/07/2026 | By News Bureau
Innovent Biologics and Takeda Finalise Global Collaboration for Next-Generation IO and ADC Therapies
As part of the agreement, Takeda will pay Innovent an upfront payment of USD1.2 billion, including a USD100 million equity investment at HKD112.56 per share.
Commercialisation Rights | 05/12/2025 | By Dineshwori | 155
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy